21,810 Shares in Zoetis Inc. $ZTS Bought by AGF Management Ltd.

AGF Management Ltd. purchased a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,810 shares of the company’s stock, valued at approximately $3,401,000.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its holdings in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares during the period. Ballentine Partners LLC raised its stake in Zoetis by 1.1% in the first quarter. Ballentine Partners LLC now owns 12,283 shares of the company’s stock valued at $2,022,000 after buying an additional 132 shares during the period. Arizona State Retirement System lifted its position in shares of Zoetis by 3.7% in the first quarter. Arizona State Retirement System now owns 135,232 shares of the company’s stock valued at $22,266,000 after buying an additional 4,794 shares during the last quarter. Stephens Inc. AR boosted its stake in shares of Zoetis by 87.3% during the 1st quarter. Stephens Inc. AR now owns 110,562 shares of the company’s stock worth $18,204,000 after acquiring an additional 51,537 shares during the period. Finally, TruNorth Capital Management LLC bought a new position in shares of Zoetis during the 1st quarter worth approximately $58,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Up 0.5%

ZTS opened at $120.20 on Monday. The stock has a fifty day moving average of $144.21 and a 200-day moving average of $152.63. The company has a market capitalization of $52.97 billion, a P/E ratio of 20.69, a P/E/G ratio of 2.31 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $117.26 and a fifty-two week high of $181.85. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the prior year, the company posted $1.58 earnings per share. Zoetis’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is currently 33.67%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on ZTS. UBS Group dropped their price target on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 5th. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partnrs downgraded shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Finally, Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Moderate Buy” and a consensus target price of $191.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.